3B BlackBio Dx Ltd (3BBLACKBIO) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- 3B BlackBio Dx Ltd reported a strong Q1 FY26, with revenue growth of 18% YoY, reaching INR 19.96 Crores.
- EBITDA increased by 11% to INR 16.19 Crores. Excluding one-time M&A expenses of INR 80 Lakhs, EBITDA growth would have been 67%.
- The company holds a 12-15% market share in the Indian molecular diagnostics market, estimated at INR 350-450 Crores.
- Aims for 15-20% growth in FY26, driven by a diverse product portfolio and strong market presence.
- Acquisition of Corus Holding SRL, parent company of Porus Bioconcept, a rapid diagnostic solutions manufacturer, for GBP 2.15 million upfront and a potential earn-out of GBP 0.605 million.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.